GeneWeave Biosciences (San Jose, CA) a development-stage molecular diagnostic company focused on using bacterial DNA for the detection of pathogens, closed a $12M Series A financing. Participants include Decheng Capital, Claremont Creek Ventures and X/Seed Capital. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C financing. Participants include Delphi Ventures, Versant Ventures, US Venture Partners and Domain Associates. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Nuclea Biotechnologies (Pittsfield, MA) a commercial-stage diagnostic company focused on in vitro companion diagnostic assays based on gene and protein expression profiles and biomarkers associated with an individual’s tumor or specific disease state, closed a $3.4M Series B financing bringing the total round to $9.8M. Participants were not identified. Note: Closing out 1Q deals. Thanx [...]

Strand Diagnostics (Indianapolis, IN) a commercial-stage molecular diagnostics company focused on DNA screening of breast and prostate biopsy samples and patient DNA for molecular cancer diagnosis verification, closed a $30M Series A financing. Participants include NantWorks. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Vascular Magnetics (Philadelphia, PA) a development-stage medical device focused on magnetically targeted drug delivery for the treatment of peripheral artery disease, closed a $7M Series A financing. Participants include Devon Park Bioventures. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

4s3 Bioscience (Medford, MA) a preclinical-stage biotherapeutics company focused on developing genetics disease therapies for orphan neuromuscular disorders, closed a $20M Series A financing. Participants include KLP Enterprises. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Promethera Biosciences (Belgium) a clinical stage biotechnology company focused on adult stem cell treatments for liver diseases, closed a $31.4 Series B financing. Participants include Vesalius Biocapital, SRIW, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Sopartec, Boehringer Ingelheim Ventures, Shire Ventures, Mitsui Global Investment, ATMI and Sambrinvest. Note: Closing out 1Q deals. Thanx for [...]

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

Jiff (Palo Alto, CA) a commercial-stage health IT company focused on a HIPAA-compliant private healthcare social network and digital health application platform, closed a $7.5M Series A financing. Participants include Aeris Capital and Aberdare Ventures.

ViewRay (Oakwood Village, OH) a clinical-stage medical device company focused on MRI-guided radiation therapy system for the treatment of various cancers, closed a $26.3M Series C financing, bringing the total round to $45M. Participants include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed and Siemens Venture Capital.

Tarsa Therapeutics (Philadelphia, PA) a clinical-stage biopharmaceutical company focused on treatments for postmenopausal osteoporosis, closed a $28 Series B financing. Participants include Foresite Capital, Novo, MVM Life Science Partners and Quaker Partners.